Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

  1. Miles, D.W.
  2. De Haas, S.L.
  3. Dirix, L.Y.
  4. Romieu, G.
  5. Chan, A.
  6. Pivot, X.
  7. Tomczak, P.
  8. Provencher, L.
  9. Cortés, J.
  10. Delmar, P.R.
  11. Scherer, S.J.
Aldizkaria:
British Journal of Cancer

ISSN: 0007-0920,  1532-1827

Argitalpen urtea: 2013

Alea: 108

Zenbakia: 5

Orrialdeak: 1052-1060

Mota: Artikulua

DOI: 10.1038/BJC.2013.69 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus